The A-Alpha Bio team. The Seattle startup generates protein interaction data and partners with drug ... A-Alpha Bio is among a growing flock of startups using AI as a tool to help scientists ...

MIAMI, May 5, 2025 /PRNewswire/ -- Immorta Bio Inc, a scientific longevity company ... "Having been chosen to present our work on using the immune system to fight cancer and aging in such an ...

CAMBRIDGE, Mass., Sept. 05, 2024 -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 study of ...

Charles River has a market capitalization of $8.89 billion. The company’s earnings yield of 6.07% compares favorably with the industry’s 3.59%. In the trailing four quarters, it delivered an ...

Chinese firms are collecting genetic data from around the world, part of an effort by the Chinese government and companies to develop the world’s largest bio-database, American intelligence ...

New Preclinical Data for AB821, Asher Bio’s CD8-Targeted IL-21 In a poster presentation entitled, “AB821 is a CD8 + T cell selective IL-21 with enhanced bioavailability that reduces CD8 + T ...

Artificial intelligence (AI) will fundamentally change medicine and healthcare: Diagnostic patient data, e.g. from ECG ... now succeeded in developing a bio-compatible implantable AI platform ...

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on targeted cell therapies for autoimmune diseases, announced that updated clinical data on its investigational therapy ...

Nevertheless, I'm "sticking my neck out" and suggesting the stock merits a "Buy" recommendation, ahead of Chronic rhinosinusitis data due before the end of this year. Upstream Bio is a clinical ...